<DOC>
	<DOCNO>NCT00537914</DOCNO>
	<brief_summary>This study perform investigate long-term safety , particular diabetogenic potential immunogenicity rhGH therapy short child bear small gestational age ( SGA ) .</brief_summary>
	<brief_title>Safety Efficacy Omnitrope® ( rhGH ) Short Children Born Small Gestational Age ( SGA )</brief_title>
	<detailed_description />
	<criteria>1 . Prepubertal ( Tanner stage I ) child bear SGA Boys : 4 year age old Girls : 4 year age old 2 . Growth disturbance chronological age sex accord country specific reference 3 . Birth weight and/or length 2 standard deviation ( SD ) gestational age 1 . Onset puberty 2 . Closed epiphyses 3 . Diabetes mellitus type I type II 4 . Fasting blood glucose great 100 mg/dl great 5.6 mmol/l measure venous blood sample 5 . Abnormal finding Oral Glucose Tolerance Test ( OGTT ) define great 140 mg/dl great 7.8 mmol/l 120 minute 6 . Acute critical illness 7 . Previous treatment hGH preparation 8 . Treatment antidiabetic medication ( e.g . metformin , insulin ) 9 . Drug abuse , substance abuse , alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Small Gestational Age , Omnitrope®/Somatropin , rhGH , SGA</keyword>
</DOC>